Codagenix Announces Close of $25 million Extension of Series B
Funding supports continued clinical studies for pediatric RSV and universal influenza vaccine candidates as well as expanded indications for oncology vertical
FARMINGDALE, N.Y. and CAMBRIDGE, Mass., Feb. 15, 2023 -- (Healthcare Sales & Marketing Network... Biopharmaceuticals, Venture Capital Codagenix, CodaVax-RSV, respiratory syncytial virus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 15, 2023 Category: Pharmaceuticals Source Type: news
Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay
SALT LAKE CITY, Feb. 15, 2023 -- (Healthcare Sales & Marketing Network) -- Sera Prognostics In... Diagnostics Sera Prognostics, PreTRM Test (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 15, 2023 Category: Pharmaceuticals Source Type: news
KeifeRx Appoints Garrett Vygantas, MD, MBA, to Board of Directors
WASHINGTON, Feb. 14, 2023 -- (Healthcare Sales & Marketing Network) -- KeifeRx, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative and immune diseases, announce... Biopharmaceuticals, Neurology, Personnel KeifeRx, tyrosine kinase inhibitor, Alzheimer's, Lewy Body Dementia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2023 Category: Pharmaceuticals Source Type: news
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix intends to seek guidance from the FDA on how to further advance HyBryte towards potential approval
PRINCETON, N.J., Feb. 14, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-... Biopharmaceuticals, Oncology, FDA Soligenix, HyBryte, synthetic hypericin, photodynamic therapy, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2023 Category: Pharmaceuticals Source Type: news
Concept Medical granted Investigational Device Exemption (IDE) approval for their Magic Touch Sirolimus Coated Balloon for the treatment of Below the Knee (BTK) Arterial Disease
TAMPA, Fla., Feb. 13, 2023 -- (Healthcare Sales & Marketing Network) -- Concept Medical Inc. (CMI), on 9th February 2023, received the Investigational Device Exemption (IDE) from the US FDA, for its Magic Touch Sirolimus Coated Balloon.
The Magic Touch... Devices, Interventional, FDA Concept Medical, Magic Touch PTA, Sirolimus, Balloon Catheter (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2023 Category: Pharmaceuticals Source Type: news
